HC Wainwright Has Positive Forecast for INO FY2024 Earnings

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) – Analysts at HC Wainwright upped their FY2024 earnings estimates for Inovio Pharmaceuticals in a research report issued on Monday, January 13th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will post earnings of ($4.19) per share for the year, up from their prior estimate of ($4.39). HC Wainwright currently has a “Neutral” rating and a $3.00 target price on the stock. The consensus estimate for Inovio Pharmaceuticals’ current full-year earnings is ($4.45) per share. HC Wainwright also issued estimates for Inovio Pharmaceuticals’ Q4 2024 earnings at ($0.87) EPS, Q1 2025 earnings at ($0.78) EPS, Q2 2025 earnings at ($0.65) EPS, Q3 2025 earnings at ($0.55) EPS, Q4 2025 earnings at ($0.50) EPS and FY2025 earnings at ($2.41) EPS.

Other research analysts have also recently issued reports about the stock. JMP Securities reissued a “market outperform” rating and set a $18.00 target price on shares of Inovio Pharmaceuticals in a research report on Friday, January 10th. Royal Bank of Canada cut their price target on shares of Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating on the stock in a report on Friday, November 15th. Finally, Oppenheimer decreased their price objective on shares of Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating for the company in a report on Monday, November 18th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. According to MarketBeat, Inovio Pharmaceuticals has an average rating of “Hold” and an average target price of $12.40.

Inovio Pharmaceuticals Trading Down 0.5 %

NASDAQ INO opened at $1.86 on Wednesday. The company’s fifty day simple moving average is $3.19 and its 200-day simple moving average is $5.97. Inovio Pharmaceuticals has a 52 week low of $1.74 and a 52 week high of $14.75. The stock has a market cap of $48.55 million, a P/E ratio of -0.89 and a beta of 0.84.

Institutional Investors Weigh In On Inovio Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the company. BNP Paribas Financial Markets increased its holdings in shares of Inovio Pharmaceuticals by 177.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 5,681 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 3,630 shares during the last quarter. MetLife Investment Management LLC increased its holdings in shares of Inovio Pharmaceuticals by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 15,167 shares of the biopharmaceutical company’s stock valued at $88,000 after acquiring an additional 8,546 shares during the last quarter. The Manufacturers Life Insurance Company bought a new stake in shares of Inovio Pharmaceuticals in the 2nd quarter valued at approximately $82,000. American Century Companies Inc. increased its holdings in shares of Inovio Pharmaceuticals by 62.2% in the 2nd quarter. American Century Companies Inc. now owns 31,565 shares of the biopharmaceutical company’s stock valued at $255,000 after acquiring an additional 12,100 shares during the last quarter. Finally, SG Americas Securities LLC bought a new stake in shares of Inovio Pharmaceuticals in the 3rd quarter valued at approximately $71,000. 26.79% of the stock is currently owned by institutional investors.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.